Mesirow Financial Investment Management, Inc. Savara Inc Transaction History

Mesirow Financial Investment Management, Inc.

$4.94 Billion
Q3 2024

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2019 Jul 12, 2019	SELL	$2.37 - $11.7 $97,956 - $483,584	-41,332 Closed	0 $0
Q1 2019 Apr 09, 2019	BUY	$6.71 - $8.6 $88,484 - $113,408	13,187 Added 46.85%	41,332 $305,000
Q3 2018 Oct 09, 2018	SELL	$10.49 - $12.87 $23,476 - $28,803	-2,238 Reduced 7.37%	28,145 $314,000
Q2 2018 Jul 11, 2018	BUY	$8.55 - $13.76 $259,774 - $418,070	30,383 New	30,383 $344,000

Others Institutions Holding SVRA

# of Institutions

129

Shares Held

158M

Call Options Held

67.6K

Put Options Held

29.4K

Nea Management Company, LLC Timonium, MD

24.5M
Shares

$82.2 Million
7.93% of portfolio
Bain Capital Life Sciences Investors, LLC Boston, MA

14.6M
Shares

$48.9 Million
11.08% of portfolio
Tcg Crossover Management, LLC Palo Alto, CA

12.4M
Shares

$41.5 Million
6.8% of portfolio
Wellington Management Group LLP Boston, MA

8.62M
Shares

$29 Million
0.01% of portfolio
Frazier Life Sciences Management, L.P. Menlo Park, CA

8.16M
Shares

$27.4 Million
1.86% of portfolio

View Full List

About Savara Inc

Ticker SVRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 114,043,000
Market Cap $383M
Description
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.

More about SVRA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Mesirow Financial Investment Management, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Mesirow Financial Investment Management, Inc. with notifications on news.

Account